Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KPI 012

Next Previous
Search
Drug Profile

KPI 012

Alternative Names: CMB 012; KPI-012

Latest Information Update: 28 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Combangio Inc
  • Developer KALA BIO
  • Class Collagens; Eye disorder therapies; Growth factors; Nerve growth factors; Peptide hydrolases; Proteins
  • Mechanism of Action Collagen replacements; Intracellular signaling peptides and protein replacements; Peptide hydrolase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Corneal injuries
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Corneal injuries
  • Preclinical Limbal stem cell deficiency; Retinitis pigmentosa; Sjogren's syndrome; Stargardt disease

Most Recent Events

  • 28 Dec 2024 No recent reports of development identified for phase-I development in Corneal injuries in Mexico (Ophthalmic, Drops)
  • 08 Aug 2024 Preclinical trials in Retinitis pigmentosa in USA (Ophthalmic)
  • 08 Aug 2024 Preclinical trials in Stargardt disease in USA (Ophthalmic)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top